219 related articles for article (PubMed ID: 22229970)
1. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
Keir CH; Vahdat LT
Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
[TBL] [Abstract][Full Text] [Related]
2. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
[TBL] [Abstract][Full Text] [Related]
4. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
Vaklavas C; Forero A
BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
[TBL] [Abstract][Full Text] [Related]
5. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Naumovski L; Junutula JR
Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
7. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
[TBL] [Abstract][Full Text] [Related]
8. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
Rose AAN; Biondini M; Curiel R; Siegel PM
Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
[TBL] [Abstract][Full Text] [Related]
10. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
[TBL] [Abstract][Full Text] [Related]
11. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
[TBL] [Abstract][Full Text] [Related]
13. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T; Robak E
Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
[TBL] [Abstract][Full Text] [Related]
14. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
15. GPNMB expression in uveal melanoma: a potential for targeted therapy.
Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
Ott PA; Hamid O; Pavlick AC; Kluger H; Kim KB; Boasberg PD; Simantov R; Crowley E; Green JA; Hawthorne T; Davis TA; Sznol M; Hwu P
J Clin Oncol; 2014 Nov; 32(32):3659-66. PubMed ID: 25267741
[TBL] [Abstract][Full Text] [Related]
19. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
20. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
Bajaj M; Heath EI
Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]